Literature DB >> 2508441

Acute and chronic inflammatory responses to local administration of recombinant IL-1 alpha, IL-beta, TNF alpha, IL-2 and Ifn gamma in mice.

C J Dunn1, M M Hardee, N D Staite.   

Abstract

The contention that cytokines are important mediators of inflammation prompted the present studies which were designed to compare acute and chronic pathological effects of locally-administered recombinant (r) IL-1 alpha, IL-1 beta, TNF alpha, IL-2 and Ifn gamma. Acute (6 hr), resolving (48 hr) inflammation was induced by the following, in order of potency: rIL-1 alpha greater than rIL-1 beta greater than rTNF alpha greater than rIfn gamma = BSA (control) following a single sc. injection. However, only rIL-1 beta and rIL-2 initiated and maintained chronic granulomatous reactions when delivered locally from a sc. ethylene vinyl acetate (EVA) slow-release polymer. The predominance of macrophages in EVA-rIL-1 beta lesions contrasted with the proliferative lymphoid granulomata induced by EVA-rIL-2 implants. These "in vivo" observations reinforce the roles of both IL-1 beta and IL-2 as potent mediators of chronic immunoinflammatory disease.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2508441     DOI： 10.1007/bf01972801

Source DB:  PubMed          Journal:  Agents Actions        ISSN： 0065-4299


  9 in total

Review 1.  Lymphokines.

Authors:  C A Dinarello; J W Mier
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

2.  Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy.

Authors:  C F Nathan; G Kaplan; W R Levis; A Nusrat; M D Witmer; S A Sherwin; C K Job; C R Horowitz; R M Steinman; Z A Cohn
Journal:  N Engl J Med       Date:  1986-07-03       Impact factor: 91.245

3.  Gamma-interferon inhibits collagen synthesis in vivo in the mouse.

Authors:  R D Granstein; G F Murphy; R J Margolis; M H Byrne; E P Amento
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

4.  Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury.

Authors:  H Z Movat; C E Burrowes; M I Cybulsky; C A Dinarello
Journal:  Am J Pathol       Date:  1987-12       Impact factor: 4.307

5.  Chemotactic effect of human recombinant interleukin 2 on mouse activated large granular lymphocytes.

Authors:  R J Natuk; R M Welsh
Journal:  J Immunol       Date:  1987-10-15       Impact factor: 5.422

6.  Increased adhesion of polymorphonuclear leukocytes to vascular endothelium by specific interaction of endogenous (interleukin-1) and exogenous (lipopolysaccharide) substances with endothelial cells 'in vitro'.

Authors:  C J Dunn; W E Fleming
Journal:  Eur J Rheumatol Inflamm       Date:  1984

7.  Interleukin 2: the molecule and its function.

Authors:  R J Robb
Journal:  Immunol Today       Date:  1984-07

8.  Polymers for sustained macromolecule release: procedures to fabricate reproducible delivery systems and control release kinetics.

Authors:  W D Rhine; D S Hsieh; R Langer
Journal:  J Pharm Sci       Date:  1980-05       Impact factor: 3.534

9.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells.

Authors:  M P Bevilacqua; J S Pober; G R Majeau; R S Cotran; M A Gimbrone
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307
  9 in total
  9 in total

1.  Correlation of leukocyte interleukin-1 production with the stimulation of prostaglandin and tissue factor synthesis by human umbilical vein endothelial cells.

Authors:  R G Schaub; C J Dunn; M R Deibel; A E Berger; D Wunderlich; W E Fleming
Journal:  Agents Actions       Date:  1990-08

2.  Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.

Authors:  R M Burch; L C Mahan
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

3.  A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon.

Authors:  M B Welborn; K Van Zee; P D Edwards; J H Pruitt; A Kaibara; J N Vauthey; M Rogy; W L Castleman; S F Lowry; J S Kenney; D Stüber; U Ettlin; B Wipf; H Loetscher; E M Copeland; W Lesslauer; L L Moldawer
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

4.  In vivo changes in plasma acute phase protein levels in the rat induced by slow release of IL-1, IL-6 and TNF.

Authors:  E J Lewis; A D Sedgwick; T H Hanahoe
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

5.  Acute phase protein response and polymorphonuclear leukocyte cathepsin g release after slow interleukin-1 stimulation in the rat.

Authors:  P Björk; T Gudmundsson; K Ohlsson
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

6.  Changes in Mobility of the Golden Hamster with Induction of an IL-1-Induced Arthritis.

Authors:  I G Otterness; M L Bliven; A J Milici
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

7.  Differential Proliferative Characteristics of Alveolar Fibroblasts in Interstitial Lung Diseases: Regulative Role of IL-1 and PGE(2).

Authors:  E Fireman; S Ben Efraim; J Greif; H Peretz; S Kivity; M Topilsky; Y Rodrig; A Yellin; R N Apte
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

8.  Interaction of interleukin-1 and interferon-gamma on fibroblast growth factor-induced angiogenesis.

Authors:  K Norioka; T Mitaka; Y Mochizuki; M Hara; M Kawagoe; H Nakamura
Journal:  Jpn J Cancer Res       Date:  1994-05

9.  Kinetics of cell migration to the dermis and hypodermis in dogs vaccinated with antigenic compounds of Leishmania braziliensis plus saponin.

Authors:  Juliana Vitoriano-Souza; Alexandre B Reis; Nádia D Moreira; Rodolfo C Giunchetti; Rodrigo Correa-Oliveira; Cláudia M Carneiro
Journal:  Vaccine       Date:  2008-05-22       Impact factor: 3.641
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.